Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
LEEN KAWAS Insider Profile
4 Followers
LEEN KAWAS, President & CEO, Director at Athira Pharma, holds ― shares in Athira Pharma (Ticker: ATHA), holds 4.39M shares in Eiger Biopharmaceuticals (Ticker: EIGRQ). Most recently, LEEN KAWAS ― shares of Athira Pharma on ― for an estimated value of ―.
LEEN KAWAS has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that LEEN KAWAS holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by LEEN KAWAS
LEEN KAWAS's Trading History
Athira Pharma
―
President & CEO, Director
―
―
Eiger Biopharmaceuticals
Nov 02, 2023
Ten Percent Owner
Informative Buy
6.33K
$11.73M
List of latest transactions for each holding click on a transaction to see LEEN KAWAS's performance on stock
You May Also Like
LEEN KAWAS insider profile FAQ
What is the percentage of profitable transactions made by LEEN KAWAS?
The percentage of profitable transactions made by LEEN KAWAS is ―.
What is the average return per transaction made by LEEN KAWAS?
The average return per transaction made by LEEN KAWAS is ―.
What stocks does LEEN KAWAS hold?
LEEN KAWAS holds: ATHA, EIGRQ stocks.
What was LEEN KAWAS’s latest transaction?
LEEN KAWAS latest transaction was an Uninformative Buy of ―.
What was LEEN KAWAS's most profitable transaction?
LEEN KAWAS’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is LEEN KAWAS's role in Athira Pharma?
LEEN KAWAS's role in Athira Pharma is President & CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.